Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven.
| Autor: | Attard G, Reid AHM, Yap TA, Raynaud F, Dowsett M, Settatree S, Barrett M, Parker C, Martins V, Folkerd E, Clark J, Cooper CS, Kaye SB, Dearnaley D, Lee G, de Bono JS, Attard, Gerhardt, Reid, Alison H M, Yap, Timothy A, Raynaud, Florence |
|---|---|
| Zdroj: | Journal of Clinical Oncology; 10/1/2008, Vol. 26 Issue 28, p4563-4571, 9p |
| Databáze: | Supplemental Index |
| Externí odkaz: |
|